Sandoz Says Xarelto Dosing Info Was Public Before Patenting

By Alex Baldwin (February 12, 2024, 7:24 PM GMT) -- Counsel for Sandoz told a London court Monday that patent protections underpinning Xarelto, Bayer's best-selling drug, are obvious, claiming that the German pharmaceutical giant published data on the dosing regimen for the key ingredient to prevent and treat blood clots before it filed the patent. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!